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Hypertension, which is characterized by small artery disease
(1), is also often associated with large artery disease,
characterized at the level of large conduit arteries by
arteriosclerosis (thickening and fibrosis of the media) and
accentuated progression of atherosclerosis (2). Increasingly
it has been appreciated that atherosclerosis has an inflam-
matory component that plays an integral role in its patho-
genesis (3), and which is also present in other conditions
associated with cardiovascular events such as hypertension
(4) and diabetes mellitus (5). Indeed, inflammation is now
recognized as a central mechanism contributing to progres-
sion of cardiovascular disease in general and may be involved
particularly in the triggering of myocardial ischemia and
infarction (6). Tissue expression and plasma concentration
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of inflammatory markers and mediators are increased in
patients with cardiovascular disease (7). These markers and
mediators of inflammation include C-reactive protein
(CRP) (7), adhesion molecules such as vascular cell adhe-
sion molecule (VCAM) and intercellular adhesion molecule
(ICAM) (7–10), chemokines such as monocyte chemotactic
protein-1 (MCP-1), as well as antifibrinolytic agents such as
plasminogen activator inhibitor-1 (PAI-1). Increased CRP
has been shown to occur in hypertension (4); in experimen-
tal hypertension, upregulation of inflammatory mediators in
tissues—such as nuclear factor kappa B (NF kappa B),
activator protein-1 (AP-1), the adhesion molecules
VCAM-1, ICAM-1, and platelet endothelial cell adhesion
molecule, and tissue factor—have been demonstrated (11).
In the presence of endothelial dysfunction that is often
found in hypertensive patients—particularly if, as often is
the case, obesity, dyslipidemia, insulin resistance, and other
manifestations of the metabolic syndrome occur (12)—
upregulation of adhesion molecules contributes to monocyte
and macrophage invasion of the vascular wall, which in the
setting of enhanced oxidative stress and generation of
oxidized low-density lipoprotein cholesterol will participate
in the development and progression of the atherosclerotic
plaque (13). Thus, endothelial dysfunction and oxidative
stress have been recognized as markers or mediators leading
to cardiovascular events (14). As inflammation is accentu-
ated, activation of matrix metalloproteinases (MMPs) by
different mechanisms triggers digestion of the fibrous cap,
precipitating its rupture and triggering cardiovascular events
(15).
Angiotensin II, via the type-1 (AT1) receptor, stimulates
nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase and enhances production of reactive oxygen species
(ROS) (16), which in turn contributes to endothelial dys-
function by inactivating nitric oxide (17), and to vascular
inflammation by stimulating NF kappa B and AP-1, and by
upregulating adhesion molecules, cytokines, and chemo-
kines (18). These events result in accelerated progression of
atherosclerosis (19). As well, angiotensin II stimulates
production of PAI-1 (20), which may contribute not only to
the prothrombotic state but also to plaque rupture. In fact,
mice in which the PAI-1 gene has been deleted are
protected from the disseminated coronary artery fibrosis and
thrombosis associated with NG-nitro-L-arginine methyl es-
ter (L-NAME) treatment and nitric oxide synthase inhibi-
tion (21). Angiotensin II also stimulates activations of
MMPs, which can digest the fibrous cap and thereby
contribute to the pathophysiology of plaque rupture (15,22).
It follows from the previous evidence that blockade of the
angiotensin AT1 receptor in hypertensive patients should
result in reduced oxidative stress, inflammatory markers,
fibrinolysis inhibition, and endothelial dysfunction. In this
issue of the Journal, Koh et al. (23) demonstrate that
hypertensive patients treated with an angiotensin receptor
blocker (ARB) (candesartan) present improved endothelial
function, diminished plasma concentration of a systemic
marker of oxidative stress (thiobarbituric acid reactive sub-
stances [TBARs] measured as malonaldehyde in plasma), as
well as tumor necrosis factor-alpha, MCP-1, and reduced
PAI-1, but no decrease in CRP, MMP-9, or fibrinogen.
There were no significant correlations of the decrease in
inflammatory markers and reduction of systolic or diastolic
blood pressure (BP), or with correction of endothelial
dysfunction, which was measured by the hyperemic re-
sponse of the brachial artery. This may suggest BP-
independent effects of renin-angiotensin blockade in hyper-
tension, as we previously proposed in the correction of small
artery remodeling by these agents (24).
If reproducible in other cohorts of patients and with other
similar antihypertensive agents, these findings may indicate
an antiatherosclerotic effect of AT1 receptor blockers as
concluded by Koh et al. (23). These data are therefore
important, but some caveats and limitations need to be
taken into account. This investigation took place over a
limited period of two months. A recent study suggested that
whereas angiotensin-converting enzyme inhibitors reduce
PAI-1 over long periods of time, ARBs do so only tran-
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siently (25). Thus, new and longer studies are necessary to
ascertain that indeed ARBs will have these beneficial effects
at least on PAI-1 with a more prolonged time-course than
suggested by these other studies (25). In addition, it needs
to be stressed that global markers of inflammation and
oxidative stress were measured. Whether increased levels of
these circulating markers do in fact reflect vascular inflam-
mation and injury and whether reductions in plasma con-
centrations are associated with vascular repair and improved
cardiovascular outcomes in hypertensive patients remains to
be demonstrated. Be it as it may, the role of angiotensin II,
initially thought to be limited to vasoconstriction, has by
now been extended to actions on the heart, the brain, the
kidney, and other organs, with a multiplicity of cardiovas-
cular and noncardiovascular effects. With respect to cardio-
vascular actions, it has become evident that angiotensin II
not only stimulates contraction but also enhances growth
and extracellular matrix deposition—particularly of collagen
and fibronectin—and stimulates apoptosis and the produc-
tion of cytokines, adhesion molecules, PAI-1, and MCP-1,
all probably to a large measure mediated by increased
oxidative stress in the vascular wall (26). Indeed, Koh et al.
(23) demonstrate a reduction in plasma TBARs in hyper-
tensive patients treated with the ARB candesartan, suggest-
ing decreased generation of ROS. Experimental and clinical
evidence over the last few years has suggested that increased
oxidative stress plays a pathophysiologic role in cardiovas-
cular disease, including atherosclerosis, hypertension, and
heart failure (27,28).
Superoxide anion and hydrogen peroxide are two of the
ROS among others that function as signaling molecules
regulating vascular tone and structure (29,30). In the vas-
culature, NAD(P)H oxidase appears to be the enzyme
primarily responsible for generation of superoxide anion
(27). The neutrophil/macrophage NAD(P)H oxidase con-
tains five subunits: p40phox (phox for PHagocyte OXidase),
p47phox, p67phox, p22phox, and gp91phox (31). p40phox,
p47phox, and p67phox occur in the cytoplasm, whereas
p22phox and gp91phox are found in the cell membrane as
cytochrome b558. Subunits of the leukocyte NAD(P)H
oxidase system are also present in non-phagocytic cells,
including cells of the vasculature (16). Angiotensin AT1
receptor activates protein kinase C, phospholipase D, or Src
(32,33) to stimulate NAD(P)H oxidase. These intermediate
steps result in phosphorylation of p47phox, which in asso-
ciation with the other cytosolic subunits translocates to the
membrane. Association with cytochrome b558 results in
formation of active NAD(P)H oxidase (34). Two low-
molecular-weight guanine nucleotide-binding proteins, Rac
2 (or Rac 1) and Rap1A also participate in the activation of
NAD(P)H oxidase. All subunits of the neutrophil
NAD(P)H oxidase are found in the three layers of the
vascular wall (31,35), although the identity of the homo-
logue of gp91phox detected in smooth muscle cells is
controversial and may depend on the species and the vessel
considered. In vascular smooth muscle cells derived from
human resistance arteries, we recently demonstrated that
gp91phox and nox4 (for NADPH OXidase) are present,
whereas nox1, which is found in rat vascular smooth muscle
(32), is undetectable in human smooth muscle cells (36).
Whether the TBARs detected in plasma in the study of Koh
et al. (23) derive mostly from ROS generated in blood
vessels, or whether there is a contribution of other organs is
unclear. Whatever their origin, it is evident that candesartan
by blocking AT1 receptors is able to reduce ROS genera-
tion, and thereby downregulate some of the proinflamma-
tory, proatherosclerotic agents generated. This is supported
by a recent publication which, using DNA microarray
technology, identified genes stimulated in response to an-
giotensin II (37) and demonstrated upregulation of inflam-
matory mediators such as osteopontin, PAI-1, MCP-1, and
tissue factor.
Together with previous data showing the proinflamma-
tory effect of angiotensin II–induced ROS leading to NF
kappa B and AP-1 upregulation (38–40), the present study
accomplishes the task of translating to the bedside our
knowledge of the pleiotropic actions of angiotensin II and
using this information to understand some of the benefits
that can be derived from blocking the pathophysiologic
cardiovascular actions of angiotensin II on AT1 receptors to
prevent complications of hypertension and progression of
vascular disease in hypertensive patients.
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